Pankaj Arora, M.D. and Harshvir S. Bal, M.D.Researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine have published a study in the American Journal of Preventive Cardiology that shows GLP-1 drugs are associated with reduced rates of heart failure worsening, arrhythmias and other adverse cardiac outcomes in patients with non-obstructive hypertrophic cardiomyopathy, commonly referred to as nHCM.
HCM causes the heart muscle to abnormally thicken, making it harder for the heart to pump blood effectively. According to the Centers for Disease Control, HCM affects roughly one in 500 people and is one of the leading causes of heart failure and sudden cardiac death in young adults. About 40 percent of HCM patients have the non-obstructive form of the disease, meaning there is no physical blockage of blood flow out of the heart. Unlike obstructive HCM, where newer targeted therapies have shown benefit, nHCM has remained a major unmet clinical need.
GLP-1 receptor agonists, including medications such as semaglutide and tirzepatide, work by mimicking a natural hormone that regulates blood sugar, appetite and metabolism. These drugs have already demonstrated cardiovascular benefits in patients with obesity and heart failure with preserved ejection fraction, a condition that shares many features with non-obstructive HCM.
This overlap prompted the UAB team to investigate whether GLP-1 receptor agonists might also help patients with non-obstructive HCM.
Key Takeways:
- GLP-1 receptor agonists were associated with substantially lower risks of heart failure, sudden cardiac death and major cardiovascular events in nHCM.
- Benefits increased with longer duration of treatment, and safety profiles were favorable, with no increased risk of pancreatitis or kidney injury.
- nHCM currently has no approved therapies, making these findings particularly important. Prospective randomized clinical trials are needed to confirm these results.
“There are currently no approved therapies specifically for non-obstructive hypertrophic cardiomyopathy, and patients with this condition have largely been left behind by recent advances in HCM treatment,” said Pankaj Arora, M.D., senior author and director of the UAB Cardiogenomics Clinic. “Our findings suggest that GLP-1 receptor agonists may offer meaningful cardiovascular protection in this underserved population.”
The study leveraged real-world data using the Research Network of the TriNetX platform to analyze health records from more than 51,000 adults with non-obstructive HCM across the United States, including 2,194 patients who were treated with a GLP-1 receptor agonist for at least six months.
After adjusting for differences in patient characteristics, the researchers found that GLP-1 receptor agonist users experienced a 56 percent lower risk of worsening heart failure, 54 percent lower risk of sudden cardiac death or dangerous heart rhythm disturbances, and 32 percent lower risk of major adverse cardiovascular events.
Harshvir S. Bal, M.D., a research fellow working under Arora at UAB and the first author of the study, notes the significance of the findings for patients who have had few options.
“For patients with non-obstructive HCM, every clinic visit can feel like a dead end because there hasn’t been a therapy proven to change the course of their disease,” Bal said. “nHCM shares many of the same underlying problems as heart failure driven by conditions like obesity and diabetes. GLP-1 receptor agonists target those mechanisms, explaining the consistent reductions in heart failure and arrhythmias across the board.”
Co-author Garima Arora, M.D., co-director of the UAB Cardiogenomics Clinic, highlights the broader significance of the findings.
“This study reinforces the idea that managing cardiometabolic health, including obesity, diabetes and high blood pressure, may be just as important as targeting the heart muscle itself in patients with nHCM. GLP-1 receptor agonists address multiple risk factors simultaneously, which explains the wide-ranging benefits we observed.”
According to Arora, these findings open a new avenue for treating a condition that has long lacked effective options.
“While randomized trials are needed to confirm these results, this study provides a strong rationale for investigating GLP-1 receptor agonists as a potential therapy for non-obstructive hypertrophic cardiomyopathy.”